ArticleJournal for immunotherapy of cancer2023

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.

Pengfei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.